15 results on '"Villagra, Alejandro"'
Search Results
2. Targeting HDAC6 improves anti-CD47 immunotherapy.
- Author
-
Gracia-Hernandez, Maria, Yende, Ashutosh S., Gajendran, Nithya, Alahmadi, Zubaydah, Li, Xintang, Munoz, Zuleima, Tan, Karen, Noonepalle, Satish, Shibata, Maho, and Villagra, Alejandro
- Subjects
- *
CELLULAR control mechanisms , *KILLER cells , *MYELOID cells , *IMMUNE checkpoint proteins , *IPILIMUMAB , *NATURAL immunity , *MICROPHTHALMIA-associated transcription factor - Abstract
Background: Cancer cells can overexpress CD47, an innate immune checkpoint that prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells. Several clinical trials have reported that CD47 blockade reduces tumor growth in hematological malignancies. However, CD47 blockade has shown modest results in solid tumors, including melanoma. Our group has demonstrated that histone deacetylase 6 inhibitors (HDAC6is) have immunomodulatory properties, such as controlling macrophage phenotype and inflammatory properties. However, the molecular and cellular mechanisms controlling these processes are not fully understood. In this study, we evaluated the role of HDAC6 in regulating the CD47/SIRPα axis and phagocytosis in macrophages. Methods: We tested the role of HDAC6is, especially Nexturastat A, in regulating macrophage phenotype and phagocytic function using bone marrow-derived macrophages and macrophage cell lines. The modulation of the CD47/SIRPα axis and phagocytosis by HDAC6is was investigated using murine and human melanoma cell lines and macrophages. Phagocytosis was evaluated via coculture assays of macrophages and melanoma cells by flow cytometry and immunofluorescence. Lastly, to evaluate the antitumor activity of Nexturastat A in combination with anti-CD47 or anti-SIRPα antibodies, we performed in vivo studies using the SM1 and/or B16F10 melanoma mouse models. Results: We observed that HDAC6is enhanced the phenotype of antitumoral M1 macrophages while decreasing the protumoral M2 phenotype. In addition, HDAC6 inhibition diminished the expression of SIRPα, increased the expression of other pro-phagocytic signals in macrophages, and downregulated CD47 expression in mouse and human melanoma cells. This regulatory role on the CD47/SIRPα axis translated into enhanced antitumoral phagocytic capacity of macrophages treated with Nexturastat A and anti-CD47. We also observed that the systemic administration of HDAC6i enhanced the in vivo antitumor activity of anti-CD47 blockade in melanoma by modulating macrophage and natural killer cells in the tumor microenvironment. However, Nexturastat A did not enhance the antitumor activity of anti-SIRPα despite its modulation of macrophage populations in the SM1 tumor microenvironment. Conclusions: Our results demonstrate the critical regulatory role of HDAC6 in phagocytosis and innate immunity for the first time, further underscoring the use of these inhibitors to potentiate CD47 immune checkpoint blockade therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers.
- Author
-
Gracia-Hernandez, Maria, Munoz, Zuleima, and Villagra, Alejandro
- Subjects
- *
DISEASE progression , *GENETIC mutation , *MELANOMA , *ONCOGENES , *IMMUNOMODULATORS , *CANCER patients , *HYDROLASES , *TUMOR suppressor genes , *EPIGENOMICS , *IMMUNOTHERAPY , *DRUG resistance in cancer cells , *CARRIER proteins , *CHEMICAL inhibitors - Abstract
Simple Summary: Melanoma affects over 300,000 people worldwide every year. Recent advancements in therapeutic treatments for melanoma patients, such as targeted therapies and immunotherapy, have improved the survival of patients without advanced disease. However, an important subset of patients remains refractory or develops resistance. Melanomagenesis, disease progression, and resistance to therapies are epigenetically regulated processes. Emerging preclinical and clinical research elucidates the mechanisms by which epigenetic drugs can prevent resistance or enhance the therapeutic efficacy of the aforementioned therapies in addition to chemotherapy, radiation therapy, and others. In this review, we assess the role of epigenetics in melanoma progression and resistance to targeted and immune therapies. Additionally, we discuss recent preclinical and clinical reports evaluating the use of epigenetic drugs as adjuvants to enhance the current therapeutic approaches for melanoma patients. Melanoma is the least common but deadliest type of skin cancer. Melanomagenesis is driven by a series of mutations and epigenetic alterations in oncogenes and tumor suppressor genes that allow melanomas to grow, evolve, and metastasize. Epigenetic alterations can also lead to immune evasion and development of resistance to therapies. Although the standard of care for melanoma patients includes surgery, targeted therapies, and immune checkpoint blockade, other therapeutic approaches like radiation therapy, chemotherapy, and immune cell-based therapies are used for patients with advanced disease or unresponsive to the conventional first-line therapies. Targeted therapies such as the use of BRAF and MEK inhibitors and immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA4 only improve the survival of a small subset of patients. Thus, there is an urgent need to identify alternative standalone or combinatorial therapies. Epigenetic modifiers have gained attention as therapeutic targets as they modulate multiple cellular and immune-related processes. Due to melanoma's susceptibility to extrinsic factors and reversible nature, epigenetic drugs are investigated as a therapeutic avenue and as adjuvants for targeted therapies and immune checkpoint inhibitors, as they can sensitize and/or reverse resistance to these therapies, thus enhancing their therapeutic efficacy. This review gives an overview of the role of epigenetic changes in melanoma progression and resistance. In addition, we evaluate the latest advances in preclinical and clinical research studying combinatorial therapies and discuss the use of epigenetic drugs such as HDAC and DNMT inhibitors as potential adjuvants for melanoma patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.
- Author
-
Moufarrij, Sara, Srivastava, Aneil, Gomez, Stephanie, Hadley, Melissa, Palmer, Erica, Austin, Paul Tran, Chisholm, Sarah, Diab, Noor, Roche, Kyle, Yu, Angela, Li, Jing, Zhu, Wenge, Lopez-Acevedo, Micael, Villagra, Alejandro, and Chiappinelli, Katherine B.
- Abstract
Novel therapies are urgently needed for ovarian cancer, the deadliest gynecologic malignancy. Ovarian cancer has thus far been refractory to immunotherapies that stimulate the host immune system to recognize and kill cancer cells. This may be because of a suppressive tumor immune microenvironment and lack of recruitment and activation of immune cells that kill cancer cells. Our previous work showed that epigenetic drugs including DNA methyltransferase inhibitors and histone deacetylase 6 inhibitors (DNMTis and HDAC6is) individually increase immune signaling in cancer cells. We find that combining DNMTi and HDAC6i results in an amplified type I interferon response, leading to increased cytokine and chemokine expression and higher expression of the MHC I antigen presentation complex in human and mouse ovarian cancer cell lines. Treating mice bearing ID8 Trp53−/− ovarian cancer with HDAC6i/DNMTi led to an increase in tumor-killing cells such as IFNg+ CD8, NK, and NKT cells and a reversal of the immunosuppressive tumor microenvironment with a decrease in MDSCs and PD-1hi CD4 T cells, corresponding with an increase in survival. Thus combining the epigenetic modulators DNMTi and HDAC6i increases anti-tumor immune signaling from cancer cells and has beneficial effects on the ovarian tumor immune microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Testing repeatability, measurement error and species differentiation when using geometric morphometrics on complex shapes: a case study of Patagonian lizards of the genus Liolaemus (Squamata: Liolaemini).
- Author
-
Vrdoljak, Juan, Sanchez, Kevin Imanol, Arreola-Ramos, Roberto, Huesa, Emilce Guadalupe Diaz, Villagra, Alejandro, Avila, Luciano Javier, and Morando, Mariana
- Subjects
- *
MEASUREMENT errors , *LIOLAEMUS , *MORPHOMETRICS , *SQUAMATA , *STATISTICAL reliability , *COLUBRIDAE - Abstract
The repeatability of findings is the key factor behind scientific reliability, and the failure to reproduce scientific findings has been termed the 'replication crisis'. Geometric morphometrics is an established tool in evolutionary biology. However, different operators (and/or different methods) could act as large sources of variation in the data obtained. Here, we investigated inter-operator error in geometric morphometric protocols on complex shapes of Liolaemus lizards, as well as measurement error in three taxa varying in their difficulty of digitalization. We also examined the potential for these protocols to discriminate among complex shapes in closely related species. We found a wide range of inter-operator error, contributing between 19.5% and 60% to the total variation. Moreover, measurement error increased with the complexity of the quantified shape. All protocols were able to discriminate between species, but the use of more landmarks did not imply better performance. We present evidence that complex shapes reduce repeatability, highlighting the need to explore different sources of variation that could lead to such low repeatability. Lastly, we suggest some recommendations to improve the repeatability and reliability of geometric morphometrics results. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy.
- Author
-
Banik, Debarati, Moufarrij, Sara, and Villagra, Alejandro
- Subjects
- *
CANCER immunotherapy , *HISTONE deacetylase inhibitors , *NEURODEGENERATION , *DRUG efficacy , *CANCER invasiveness - Abstract
Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors (HDACis) have positioned these agents as promising drug candidates in combatting cancer, autoimmune, neurodegenerative, and infectious diseases. The same has also encouraged the evaluation of multiple HDACi candidates in preclinical studies in cancer and other diseases as well as the FDA-approval towards clinical use for specific agents. In this review, we have discussed how the efficacy of immunotherapy can be leveraged by combining it with HDACis. We have also included a brief overview of the classification of HDACis as well as their various roles in physiological and pathophysiological scenarios to target key cellular processes promoting the initiation, establishment, and progression of cancer. Given the critical role of the tumor microenvironment (TME) towards the outcome of anticancer therapies, we have also discussed the effect of HDACis on different components of the TME. We then have gradually progressed into examples of specific pan-HDACis, class I HDACi, and selective HDACis that either have been incorporated into clinical trials or show promising preclinical effects for future consideration. Finally, we have included examples of ongoing trials for each of the above categories of HDACis as standalone agents or in combination with immunotherapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.
- Author
-
Woods, David M., Woan, Karrune V., Fengdong Cheng, Sodré, Andressa L., Dapeng Wang, Yongxia Wu, Zi Wang, Jie Chen, Powers, John, Pinilla-Ibarz, Javier, Yu Yu, Ya Zhang, Xuefeng Wu, Xiaoyan Zheng, Weber, Jeffrey, Hancock, Wayne W., Seto, Edward, Villagra, Alejandro, Xue-Zhong Yu, and Sotomayor, Eduardo M.
- Subjects
- *
MOUSE leukemia , *T cells , *HISTONE acetylation , *ENZYMES , *PHENOTYPES , *HISTONE deacetylase , *CYTOKINES , *CHROMATIN - Abstract
Histone acetylation and the families of enzymes responsible for controlling these epigenetic marks have been implicated in regulating T-cell maturation and phenotype. Here, we demonstrate a previously undefined role of histone deacetylase 11 (HDAC11) in regulating T-cell effector functions. Using EGFP-HDAC11 transgenic reporter mice, we found that HDAC11 expression was lower in effector relative to naive and central memory T-cell populations, and activation of resting T cells resulted in its decreased expression. Experiments using HDAC11 knockout (KO) mice revealed that T cells from these mice displayed enhanced proliferation, proinflammatory cytokine production, and effector molecule expression. In addition, HDAC11KO T cells had increased expression of Eomesodermin (Eomes) and TBX21 (Tbet), transcription factors previously shown to regulate inflammatory cytokine and effector molecule production. Conversely, over-expression of HDAC11 resulted in decreased expression of these genes. Chromatin immunoprecipitation showed the presence of HDAC11 at the Eomes and Tbet gene promoters in resting T cells, where it rapidly disassociated following T-cell activation. In vivo, HDAC11KO T cells were refractory to tolerance induction.HDAC11KOT cells also mediated accelerated onset of acute graft-versus-host disease (GVHD) in a murine model, characterized by increased proliferation of T cells and expression of interferon-g, tumor necrosis factor, and EOMES. In addition, adoptive transfer of HDAC11KO T cells resulted in significantly reduced tumor burden in a murine B-cell lymphoma model. Taken together, these data demonstrate a previously unknown role of HDAC11 as a negative epigenetic regulator of T-cell effector phenotype and function. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function.
- Author
-
Sahakian, Eva, Powers, John J., Chen, Jie, Deng, Susan L., Cheng, Fengdong, Distler, Allison, Woods, David M., Rock-Klotz, Jennifer, Sodre, Andressa L., Youn, Je-In, Woan, Karrune V., Villagra, Alejandro, Gabrilovich, Dmitry, Sotomayor, Eduardo M., and Pinilla-Ibarz, Javier
- Subjects
- *
HISTONE deacetylase , *EPIGENETICS , *SUPPRESSOR cells , *CELL populations , *ANTINEOPLASTIC agents , *CANCER immunotherapy - Abstract
Myeloid-derived suppressor cells (MDSCs), a heterogeneous population of cells capable of suppressing anti-tumor T cell function in the tumor microenvironment, represent an imposing obstacle in the development of cancer immunotherapeutics. Thus, identifying elements essential to the development and perpetuation of these cells will undoubtedly improve our ability to circumvent their suppressive impact. HDAC11 has emerged as a key regulator of IL-10 gene expression in myeloid cells, suggesting that this may represent an important targetable axis through which to dampen MDSC formation. Using a murine transgenic reporter model system where eGFP expression is controlled by the HDAC11 promoter (Tg-HDAC11-eGFP), we provide evidence that HDAC11 appears to function as a negative regulator of MDSC expansion/function in vivo . MDSCs isolated from EL4 tumor-bearing Tg-HDAC11-eGFP display high expression of eGFP, indicative of HDAC11 transcriptional activation at steady state. In striking contrast, immature myeloid cells in tumor-bearing mice display a diminished eGFP expression, implying that the transition of IMC to MDSC's require a decrease in the expression of HDAC11, where we postulate that it acts as a gate-keeper of myeloid differentiation. Indeed, tumor-bearing HDAC11-knockout mice (HDAC11-KO) demonstrate a more suppressive MDSC population as compared to wild-type (WT) tumor-bearing control. Notably, the HDAC11-KO tumor-bearing mice exhibit enhanced tumor growth kinetics when compare to the WT control mice. Thus, through a better understanding of this previously unknown role of HDAC11 in MDSC expansion and function, rational development of targeted epigenetic modifiers may allow us to thwart a powerful barrier to efficacious immunotherapies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. c-Abl Stabilizes HDAC2 Levels by Tyrosine Phosphorylation Repressing Neuronal Gene Expression in Alzheimer’s Disease.
- Author
-
Gonzalez-Zuñiga, Marcelo, Contreras, Pablo S., Estrada, Lisbell D., Chamorro, David, Villagra, Alejandro, Zanlungo, Silvana, Seto, Edward, and Alvarez, Alejandra R.
- Subjects
- *
TYROSINE , *PHOSPHORYLATION , *GENE expression , *ALZHEIMER'S disease , *GENETIC transcription , *POST-translational modification , *DRUG therapy , *IMATINIB - Abstract
Summary In Alzheimer’s disease (AD), there is a decrease in neuronal gene expression induced by HDAC2 increase; however, the mechanisms involved are not fully elucidated. Here, we described how the tyrosine kinase c-Abl increases HDAC2 levels, inducing transcriptional repression of synaptic genes. Our data demonstrate that (1) in neurons, c-Abl inhibition with Imatinib prevents the AβO-induced increase in HDAC2 levels; (2) c-Abl knockdown cells show a decrease in HDAC2 levels, while c-Abl overexpression increases them; (3) c-Abl inhibition reduces HDAC2-dependent repression activity and HDAC2 recruitment to the promoter of several synaptic genes, increasing their expression; (4) c-Abl induces tyrosine phosphorylation of HDAC2, a posttranslational modification, affecting both its stability and repression activity; and (5) treatment with Imatinib decreases HDAC2 levels in a transgenic mice model of AD. Our results support the participation of the c-Abl/HDAC2 signaling pathway in the epigenetic blockade of gene expression in AD pathology. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs.
- Author
-
Fengdong Cheng, Lienlaf, Maritza, Hong-Wei Wang, Perez-Villarroel, Patricio, Lee, Calvin, Woan, Karrune, Rock-Klotz, Jennifer, Sahakian, Eva, Woods, David, Pinilla-Ibarz, Javier, Kalin, Jay, Jianguo Tao, Hancock, Wayne, Kozikowski, Alan, Seto, Edward, Villagra, Alejandro, and Sotomayor, Eduardo M.
- Subjects
- *
T cells , *HISTONE deacetylase , *GENETIC regulation of enzymes , *NUCLEOTIDE sequence , *CYTOPLASMIC inheritance - Abstract
APCs are critical in T cell activation and in the induction of T cell tolerance. Epigenetic modifications of specific genes in the APC play a key role in this process, and among them histone deacetylases (HDACs) have emerged as key participants. HDAC6, one of the members of this family of enzymes, has been shown to be involved in regulation of inflammatory and immune responses. In this study, to our knowledge we show for the first time that genetic or pharmacologic disruption of HDAC6 in macrophages and dendritic cells results in diminished production of the immunosuppressive cytokine IL-10 and induction of inflammatory APCs that effectively activate Ag-specific naive T cells and restore the responsiveness of anergic CD4+ T cells. Mechanistically, we have found that HDAC6 forms a previously unknown molecular complex with STAT3, association that was detected in both the cytoplasmic and nuclear compartments of the APC. By using HDAC6 recombinant mutants we identified the domain comprising amino acids 503-840 as being required for HDAC6 interaction with STAT3. Furthermore, by re-chromatin immunoprecipitation we confirmed that HDAC6 and STAT3 are both recruited to the same DNA sequence within the Il10 gene promoter. Of note, disruption of this complex by knocking down HDAC6 resulted in decreased STAT3 phosphorylation--but no changes in STAT3 acetylation--as well as diminished recruitment of STAT3 to the Il10 gene promoter region. The additional demonstration that a selective HDAC6 inhibitor disrupts this STAT3/IL-10 tolerogenic axis points to HDAC6 as a novel molecular target in APCs to overcome immune tolerance and tips the balance toward T cell immunity. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells.
- Author
-
Cheng, Fengdong, Lienlaf, Maritza, Perez-Villarroel, Patricio, Wang, Hong-Wei, Lee, Calvin, Woan, Karrune, Woods, David, Knox, Tessa, Bergman, Joel, Pinilla-Ibarz, Javier, Kozikowski, Alan, Seto, Edward, Sotomayor, Eduardo M., and Villagra, Alejandro
- Subjects
- *
HISTONE deacetylase regulation , *GENETIC regulation , *GENETIC transcription , *INTERLEUKIN-10 , *ANTIGEN presenting cells , *T cells - Abstract
Highlights: [•] HDAC6 interacts with HDAC11 in antigen presenting cells. [•] HDAC6 is a positive regulator of IL10 production. [•] Nuclear role of HDAC6 as transcriptional regulator. [•] HDACs as modulators of the APC plasticity to trigger T-cell activation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Author Correction: Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.
- Author
-
Moufarrij, Sara, Srivastava, Aneil, Gomez, Stephanie, Hadley, Melissa, Palmer, Erica, Austin, Paul Tran, Chisholm, Sarah, Diab, Noor, Roche, Kyle, Yu, Angela, Li, Jing, Zhu, Wenge, Lopez-Acevedo, Micael, Villagra, Alejandro, and Chiappinelli, Katherine B.
- Subjects
- *
OVARIAN cancer , *OVARIAN tumors - Published
- 2021
- Full Text
- View/download PDF
13. Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma.
- Author
-
Ledezma, Debbie K., Balakrishnan, Preethi B., Cano-Mejia, Juliana, Sweeney, Elizabeth E., Hadley, Melissa, Bollard, Catherine M., Villagra, Alejandro, and Fernandes, Rohan
- Subjects
- *
DACARBAZINE , *EPIGENETICS , *MELANOMA , *MAJOR histocompatibility complex , *INDOCYANINE green , *NANOPARTICLES - Abstract
In this study, we describe poly (lactic-co-glycolic) acid (PLGA)-based nanoparticles that combine photothermal therapy (PTT) with epigenetic therapy for melanoma. Specifically, we co-encapsulated indocyanine green (ICG), a PTT agent, and Nexturastat A (NextA), an epigenetic drug within PLGA nanoparticles (ICG-NextA-PLGA; INAPs). We hypothesized that combining PTT with epigenetic therapy elicits favorable cytotoxic and immunomodulatory responses that result in improved survival in melanoma-bearing mice. We utilized a nanoemulsion synthesis scheme to co-encapsulate ICG and NextA within stable and monodispersed INAPs. The INAPs exhibited concentration-dependent and near-infrared (NIR) laser power-dependent photothermal heating characteristics, and functioned as effective single-use agents for PTT of melanoma cells in vitro. The INAPs functioned as effective epigenetic therapy agents by inhibiting the expression of pan-histone deacetylase (HDAC) and HDAC6-specific activity in melanoma cells in vitro. When used for both PTT and epigenetic therapy in vitro, the INAPs increased the expression of co-stimulatory molecules and major histocompatibility complex (MHC) Class I in melanoma cells relative to controls. These advantages persisted in vivo in a syngeneic murine model of melanoma, where the combination therapy slowed tumor progression and improved median survival. These findings demonstrate the potential of INAPs as agents of PTT and epigenetic therapy for melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
- Author
-
Knox, Tessa, Sahakian, Eva, Banik, Debarati, Hadley, Melissa, Palmer, Erica, Noonepalle, Satish, Kim, Jennifer, Powers, John, Gracia-Hernandez, Maria, Oliveira, Vasco, Cheng, Fengdong, Chen, Jie, Barinka, Cyril, Pinilla-Ibarz, Javier, Lee, Norman H., Kozikowski, Alan, and Villagra, Alejandro
- Subjects
- *
HISTONE deacetylase inhibitors , *MACROPHAGES , *CANCER cells - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Epigenetic therapy for ovarian cancer: promise and progress.
- Author
-
Moufarrij, Sara, Dandapani, Monica, Arthofer, Elisa, Gomez, Stephanie, Srivastava, Aneil, Lopez-Acevedo, Micael, Villagra, Alejandro, and Chiappinelli, Katherine B.
- Subjects
- *
OVARIAN cancer , *GYNECOLOGIC cancer - Abstract
Ovarian cancer is the deadliest gynecologic malignancy, with a 5-year survival rate of approximately 47%, a number that has remained constant over the past two decades. Early diagnosis improves survival, but unfortunately only 15% of ovarian cancers are diagnosed at an early or localized stage. Most ovarian cancers are epithelial in origin and treatment prioritizes surgery and cytoreduction followed by cytotoxic platinum and taxane chemotherapy. While most tumors will initially respond to this treatment, recurrence is likely to occur within a median of 16 months for patients who present with advanced stage disease. New treatment options separate from traditional chemotherapy that take advantage of advances in understanding of the pathophysiology of ovarian cancer are needed to improve outcomes. Recent work has shown that mutations in genes encoding epigenetic regulators are mutated in ovarian cancer, driving tumorigenesis and resistance to treatment. Several of these epigenetic modifiers have emerged as promising drug targets for ovarian cancer therapy. In this article, we delineate epigenetic abnormalities in ovarian cancer, discuss key scientific advances using epigenetic therapies in preclinical ovarian cancer models, and review ongoing clinical trials utilizing epigenetic therapies in ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.